Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.32 |
| ▸ | HTR2A | P28223 | 5/20 | 0.32 |
| ▸ | HTR7 | P34969 | 5/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008981 | 0.70 | CPA1 (0.34) | — | |
| SCHEMBL24851500 | 0.61 | DPP4 (0.40) | OPRM1HTR2AHTR7DRD2CCR5 | |
| SCHEMBL12384497 | 0.60 | SLC18A3 (0.37) | OPRM1DRD2 | |
| SCHEMBL10442555 | 0.60 | SLC18A3 (0.37) | OPRM1DRD2 | |
| SCHEMBL15837588 | 0.60 | DRD2 (0.40) | SIGMAR1DRD2 | |
| SCHEMBL21397315 | 0.60 | DRD2 (0.40) | SIGMAR1DRD2 | |
| SCHEMBL16980431 | 0.60 | DRD2 (0.40) | SIGMAR1DRD2 | |
| SCHEMBL26171348 | 0.59 | POLB (0.44) | OPRM1HTR7KCNH2DRD2CCR5 | |
| SCHEMBL21064707 | 0.58 | KDM5A (0.33) | — | |
| SCHEMBL20232928 | 0.58 | GAA (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | OPRM1 2267/4885HTR2A 3863/4885HTR7 2584/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | OPRM1 2267/4885HTR2A 3863/4885HTR7 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.